<DOC>
	<DOCNO>NCT00435825</DOCNO>
	<brief_summary>This 4 arm study compare efficacy safety PEGASYS give 24 48 week , dose 90 180 microgram weekly , treatment HBeAg positive patient chronic hepatitis B . Patients randomize one 4 treatment group : ) PEGASYS 90 microgram subcutaneous ( sc ) weekly 24 week , b ) PEGASYS 180 microgram sc weekly 24 week , c ) PEGASYS 90 microgram sc weekly 48 week ) PEGASYS 180 microgram sc weekly 48 week . Following treatment 24 week period treatment-free follow-up treatment group primary endpoint . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Patients With Hepatitis Be Antigen ( HBeAg ) Positive Chronic Hepatitis B ( CHB ) .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; positive Hepatitis B surface antigen ( HBsAg ) &gt; 6 month , positive HBeAg , HBV DNA &gt; 500,000 copies/mL , antiHBs negative ; liver disease consistent Chronic Hepatitis B. antiviral therapy CHB within previous 6 month ; coinfection Hepatitis A virus ( HAV ) , Hepatitis C virus ( HCV ) , Hepatitis D virus ( HDV ) Human immuno deficiency virus ( HIV ) ; evidence decompensated liver disease ; medical condition associate chronic liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>